NC Biomatrix: Regenerative Biomaterials for European Strategic Autonomy
34 pages · PDF · 18 August 2025 · Licensed single-user copy, watermarked to the buyer
€499 excl. VAT — EU VAT calculated at checkout (VAT ID accepted for reverse charge); invoice issued after payment
One click to Stripe — guest checkout, no account. Your download appears on the confirmation page and arrives by e-mail right after payment (link valid 72 hours, up to 5 downloads).
About this report
NC Biomatrix B.V. is a Dutch deep-tech venture pioneering regenerative biomaterials to combat chronic back pain. Based in Eindhoven and spun out of research at TU Eindhoven in 2019, the company has developed an injectable gel that can restore degenerated spinal discs and alleviate pain .
This proprietary biomatrix, derived from biological matrix proteins, offers a non-surgical alternative to spinal fusion or artificial disc implants. Led by an international team of biomedical innovators, NC Biomatrix is translating cutting-edge lab discoveries into a tangible therapy for millions suffering from degenerative disc disease.
Key questions this report answers
- How does NC Biomatrix's injectable regenerative biomatrix gel restore degenerated spinal discs as a non-surgical alternative to fusion or implants?
- What is the clinical and technology readiness of the biomatrix therapy, and how does it fit European strategic health autonomy?
- Which research partners, clinical customers and dual-use medical markets does the TU Eindhoven spin-out target?
- What capability gaps, dependencies and strategic indicators shape NC Biomatrix's path to market?
Inside this report
- Executive Summary
- 1. Corporate Identity & Legal Structure
- 2. Strategic Business Profile
- 3. Technology Portfolio Mapping
- 4. Technology Readiness Assessment
- 5. European Strategic Program Participation
- 6. Academic & Research Origins
- 7. Dual-Use Applications & European Market Strategy
- 8. Strategic Partnerships & European Industrial Alliances
- 9. European Market Focus & Operational Domains
- 10. Intellectual Property & European Innovation Assets
- 11. Leadership & European Technical Expertise
- 12. Capability and Gap Analysis
- 13. Strategic Indicators & European Innovation Metrics
Who it's for
Investors screening NC Biomatrix B.V., competitors and partners assessing their position, and analysts who need a sourced, structured account of the entity and its technology.
Related reports
Methodology, format & delivery
DFM reports are built from primary and official sources — TED procurement notices, CORDIS and the EU Funding & Tenders Portal, EIB operations, the NATO Innovation Fund portfolio, SIPRI data, official budget documents and company disclosures — read together with the underlying legal texts. Sources are cited in the document; it reflects them as of its publication date (18 August 2025). You receive a 34-page PDF, watermarked to you on every page, delivered on the confirmation page and by e-mail immediately after checkout (personal link valid 72 hours, up to 5 downloads). Guest checkout, single-user licence — Terms of Sale.
Related on DFM
More Tactical reports · Military Medical Tech · All reports
Prefer unlimited access?
Prefer unlimited access? Every report like this is included in the DFM Analysis subscription. See plans →